Chertow GM, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482−2494. doi: 10.1056/NEJMoa1205624

• PubMed
Chertow GM, Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482−2494. doi: 10.1056/NEJMoa1205624)| false
• Search Google Scholar
• Export Citation

Block GA, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials. JAMA 2017; 317:146−155. doi: 10.1001/jama.2016.19456

• PubMed
Block GA, Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials. JAMA 2017; 317:146−155. doi: 10.1001/jama.2016.19456)| false
• Search Google Scholar
• Export Citation

Block GA, et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J Am Soc Nephrol 2019; 30:641−652. doi: 10.1681/ASN.2018080832

• PubMed
Block GA, Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J Am Soc Nephrol 2019; 30:641−652. doi: 10.1681/ASN.2018080832)| false
• Search Google Scholar
• Export Citation

Ardelyx Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis. Published December 3, 2019. Accessed December 25, 2020. https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-topline-results-pivotal-phase-3

• PubMed
Ardelyx Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis. Published December 3, 2019. Accessed December 25, 2020. https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-topline-results-pivotal-phase-3)| false
• Search Google Scholar
• Export Citation

Block GA, et al. A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 2019; 30:1495−1504. doi: 10.1681/ASN.2018101016

• PubMed
Block GA, A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 2019; 30:1495−1504. doi: 10.1681/ASN.2018101016)| false
• Search Google Scholar
• Export Citation

Edmonston DL, et al. Design and rationale of HiLo: A pragmatic, randomized trial of phosphate management for patients on maintenance hemodialysis. Am J Kidney Dis [published online ahead of print December 3, 2020]. doi: 10.1053/j.ajkd.2020.10.008; https://www.ajkd.org/article/S0272-6386(20)31131-8/fulltext

• PubMed
Edmonston DL, Design and rationale of HiLo: A pragmatic, randomized trial of phosphate management for patients on maintenance hemodialysis. Am J Kidney Dis [published online ahead of print December 3, 2020]. doi: 10.1053/j.ajkd.2020.10.008; https://www.ajkd.org/article/S0272-6386(20)31131-8/fulltext)| false
• Search Google Scholar
• Export Citation

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE). ClinicalTrials.gov: NCT03573089. https://clinicaltrials.gov/ct2/show/NCT03573089

• PubMed
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE). ClinicalTrials.gov: NCT03573089. https://clinicaltrials.gov/ct2/show/NCT03573089)| false
• Export Citation